Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant irisin
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant irisin is a laboratory-produced version of the muscle-derived hormone irisin, which is naturally released into the circulation during physical exercise. Irisin is the cleaved extracellular fragment of the transmembrane protein fibronectin type III domain-containing protein 5 (FNDC5). In preclinical models of ischemic stroke, recombinant irisin has demonstrated neuroprotective effects by attenuating neuroinflammation. Its mechanism involves the suppression of inflammasome assembly—specifically reducing levels of apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC) and caspase-1—and the modulation of microglial phenotypes from a pro-inflammatory amoeboid state to a more ramified, homeostatic state. While primarily used as a research reagent, it is being investigated for its potential therapeutic applications in metabolic and neurological disorders.
- Other names
- irisinFNDC5FNDC-5FNDC 5
02
Targets
PYCARD (Apoptosis-associated speck-like protein containing a CARD)CASP1 (Caspase-1)αVβ1 (Integrin alpha-V beta-1)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on recombinant irisin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant irisin.